EarningsNPCE reported 2Q25 sales of $23.5 million, which is 2% higher than consensus and shows a year-over-year growth of 22%.
Regulatory ProgressFDA discussions for IGE are progressing well, with an expected accelerated review timeline following PMA supplement submission.
Revenue GuidanceRevenue guidance for NPCE has been raised more than the beat, indicating confidence in the company's future performance.